Background The association between cortisol secretion and mortality in patients with adrenal incidentalomas is controversial. We aimed to assess all-cause mortality, prevalence of comorbidities, and occurrence of cardiovascular events in uniformly stratified patients with adrenal incidentalomas and cortisol autonomy (defined as non-suppressible serum cortisol on dexamethasone suppression testing).Methods We conducted an international, retrospective, cohort study (NAPACA Outcome) at 30 centres in 16 countries. Eligible patients were aged 18 years or older with an adrenal incidentaloma (diameter >= 1 cm) detected between Jan 1, 1996, and Dec 31, 2015, and availability of a 1 mg dexamethasone suppression test result from the time of the initial diagnosis. Patients with clinically apparent hormone excess, active malignancy, or follow-up of less than 36 months were excluded. Patients were stratified according to the 0800-0900 h serum cortisol values after an overnight 1 mg dexamethasone suppression test; less than 50 nmol/L was classed as non-functioning adenoma, 50-138 nmol/L as possible autonomous cortisol secretion, and greater than 138 nmol/L as autonomous cortisol secretion. The primary endpoint was all-cause mortality. Secondary endpoints were the prevalence of cardiometabolic comorbidities, cardiovascular events, and cause-specific mortality. The primary and secondary endpoints were assessed in all study participants.Findings Of 4374 potentially eligible patients, 3656 (2089 [57.1%] with non-functioning adenoma, 1320 [36.1%] with possible autonomous cortisol secretion, and 247 [6.8%] with autonomous cortisol secretion) were included in the study cohort for mortality analysis (2350 [64.3%] women and 1306 [35.7%] men; median age 61 years [IQR 53-68]; median follow-up 7.0 years [IQR 4.7-10.2]). During follow-up, 352 (9.6%) patients died. All-cause mortality (adjusted for age, sex, comorbidities, and previous cardiovascular events) was significantly increased in patients with possible autonomous cortisol secretion (HR 1.52, 95% CI 1.19-1.94) and autonomous cortisol secretion (1.77, 1.20-2.62) compared with patients with non-functioning adenoma. In women younger than 65 years, autonomous cortisol secretion was associated with higher all-cause mortality than non-functioning adenoma (HR 4.39, 95% CI 1.93-9.96), although this was not observed in men. Cardiometabolic comorbidities were significantly less frequent with non-functioning adenoma than with possible autonomous cortisol secretion and autonomous cortisol secretion (hypertension occurred in 1186 [58.6%] of 2024 patients with non-functioning adenoma, 944 [74.0%] of 1275 with possible autonomous cortisol secretion, and 179 [75.2%] of 238 with autonomous cortisol secretion; dyslipidaemia occurred in 724 [36.2%] of 1999 patients, 547 [43.8%] of 1250, and 123 [51.9%] of 237; and any diabetes occurred in 365 [18.2%] of 2002, 288 [23.0%] of 1250, and 62 [26.7%] of 232; all p values <0.001).Interpretation Cortisol autonomy is associated with increased all-cause mortality, particularly in women younger than 65 years. However, until results from randomised interventional trials are available, a conservative therapeutic approach seems to be justified in most patients with adrenal incidentaloma. Copyright (c) 2022 Elsevier Ltd. All rights reserved.

Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study

Reimondo, Giuseppe
Co-first
;
Puglisi, Soraya;Pagotto, Uberto;Terzolo, Massimo
Co-last
;
2022-01-01

Abstract

Background The association between cortisol secretion and mortality in patients with adrenal incidentalomas is controversial. We aimed to assess all-cause mortality, prevalence of comorbidities, and occurrence of cardiovascular events in uniformly stratified patients with adrenal incidentalomas and cortisol autonomy (defined as non-suppressible serum cortisol on dexamethasone suppression testing).Methods We conducted an international, retrospective, cohort study (NAPACA Outcome) at 30 centres in 16 countries. Eligible patients were aged 18 years or older with an adrenal incidentaloma (diameter >= 1 cm) detected between Jan 1, 1996, and Dec 31, 2015, and availability of a 1 mg dexamethasone suppression test result from the time of the initial diagnosis. Patients with clinically apparent hormone excess, active malignancy, or follow-up of less than 36 months were excluded. Patients were stratified according to the 0800-0900 h serum cortisol values after an overnight 1 mg dexamethasone suppression test; less than 50 nmol/L was classed as non-functioning adenoma, 50-138 nmol/L as possible autonomous cortisol secretion, and greater than 138 nmol/L as autonomous cortisol secretion. The primary endpoint was all-cause mortality. Secondary endpoints were the prevalence of cardiometabolic comorbidities, cardiovascular events, and cause-specific mortality. The primary and secondary endpoints were assessed in all study participants.Findings Of 4374 potentially eligible patients, 3656 (2089 [57.1%] with non-functioning adenoma, 1320 [36.1%] with possible autonomous cortisol secretion, and 247 [6.8%] with autonomous cortisol secretion) were included in the study cohort for mortality analysis (2350 [64.3%] women and 1306 [35.7%] men; median age 61 years [IQR 53-68]; median follow-up 7.0 years [IQR 4.7-10.2]). During follow-up, 352 (9.6%) patients died. All-cause mortality (adjusted for age, sex, comorbidities, and previous cardiovascular events) was significantly increased in patients with possible autonomous cortisol secretion (HR 1.52, 95% CI 1.19-1.94) and autonomous cortisol secretion (1.77, 1.20-2.62) compared with patients with non-functioning adenoma. In women younger than 65 years, autonomous cortisol secretion was associated with higher all-cause mortality than non-functioning adenoma (HR 4.39, 95% CI 1.93-9.96), although this was not observed in men. Cardiometabolic comorbidities were significantly less frequent with non-functioning adenoma than with possible autonomous cortisol secretion and autonomous cortisol secretion (hypertension occurred in 1186 [58.6%] of 2024 patients with non-functioning adenoma, 944 [74.0%] of 1275 with possible autonomous cortisol secretion, and 179 [75.2%] of 238 with autonomous cortisol secretion; dyslipidaemia occurred in 724 [36.2%] of 1999 patients, 547 [43.8%] of 1250, and 123 [51.9%] of 237; and any diabetes occurred in 365 [18.2%] of 2002, 288 [23.0%] of 1250, and 62 [26.7%] of 232; all p values <0.001).Interpretation Cortisol autonomy is associated with increased all-cause mortality, particularly in women younger than 65 years. However, until results from randomised interventional trials are available, a conservative therapeutic approach seems to be justified in most patients with adrenal incidentaloma. Copyright (c) 2022 Elsevier Ltd. All rights reserved.
2022
10
7
499
508
https://www.thelancet.com/action/showPdf?pii=S2213-8587(22)00100-0
Cohort Studies; Dexamethasone; Female; Humans; Hydrocortisone; Male; Middle Aged; Retrospective Studies; Adenoma; Adrenal Gland Neoplasms; Hypertension
Deutschbein, Timo; Reimondo, Giuseppe; Di Dalmazi, Guido; Bancos, Irina; Patrova, Jekaterina; Vassiliadi, Dimitra Argyro; Nekić, Anja Barač; Debono, Miguel; Lardo, Pina; Ceccato, Filippo; Petramala, Luigi; Prete, Alessandro; Chiodini, Iacopo; Ivović, Miomira; Pazaitou-Panayiotou, Kalliopi; Alexandraki, Krystallenia I; Hanzu, Felicia Alexandra; Loli, Paola; Yener, Serkan; Langton, Katharina; Spyroglou, Ariadni; Kocjan, Tomaz; Zacharieva, Sabina; Valdés, Nuria; Ambroziak, Urszula; Suzuki, Mari; Detomas, Mario; Puglisi, Soraya; Tucci, Lorenzo; Delivanis, Danae Anastasia; Margaritopoulos, Dimitris; Dusek, Tina; Maggio, Roberta; Scaroni, Carla; Concistrè, Antonio; Ronchi, Cristina Lucia; Altieri, Barbara; Mosconi, Cristina; Diamantopoulos, Aristidis; Iñiguez-Ariza, Nicole Marie; Vicennati, Valentina; Pia, Anna; Kroiss, Matthias; Kaltsas, Gregory; Chrisoulidou, Alexandra; Marina, Ljiljana V; Morelli, Valentina; Arlt, Wiebke; Letizia, Claudio; Boscaro, Marco; Stigliano, Antonio; Kastelan, Darko; Tsagarakis, Stylianos; Athimulam, Shobana; Pagotto, Uberto; Maeder, Uwe; Falhammar, Henrik; Newell-Price, John; Terzolo, Massimo; Fassnacht, Martin
File in questo prodotto:
File Dimensione Formato  
NAPACA Outcome - Main Manuscript - 22-03-09 clean version.pdf

Accesso aperto

Descrizione: manoscritto
Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 191.29 kB
Formato Adobe PDF
191.29 kB Adobe PDF Visualizza/Apri
NAPACA Outcome Study - Supplementals 2022-04-11.pdf

Accesso aperto

Descrizione: supplemento 1
Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 118.13 kB
Formato Adobe PDF
118.13 kB Adobe PDF Visualizza/Apri
NAPACA Outcome Study - Supplementals 2022-04-11.3.pdf

Accesso aperto

Descrizione: supplemento 2
Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 698.13 kB
Formato Adobe PDF
698.13 kB Adobe PDF Visualizza/Apri
NAPACA Outcome Study - Supplementals 2022-04-11.2.pdf

Accesso aperto

Descrizione: supplemento 3
Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 81.29 kB
Formato Adobe PDF
81.29 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1876318
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 50
social impact